Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome

COVID-19 Clinical Trial

Official title:

Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in SARS-Cov-2 Infected Patients With a Systemic Inflammatory Response Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04346017
• Other study ID #: CHUB-IL6-COVID-19
• Status: Completed
• Phase: N/A
• Start date: March 20, 2020
• Est. completion date: November 23, 2020

Study information

• Verified date: September 2021
• Source: Brugmann University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In patients infected by the SARS-Cov-2 Coronavirus a severely progressive disease requiring hospitalization in intensive care seems related to deregulation of cytokines with very high levels of IL-6, IL-2, IL-7, IL-10 and TNF-α. In order to elucidate the mechanism of this hyper inflammatory syndrome we will measure a panel of pro and anti inflammatory cytokines, as well as known markers of macrophage activation syndrome.

To determine the role of activation of the complement cascade the most important complement factors and their activation markers will be measured.

The changes of those parameters will be monitored after administration of an anti-IL6R antibody therapy.

Description:

In patients with severely progressive SARS-Cov-2 Coronavirus infection, the elderly and immunocompromised are at greater risk of progressing to a serious image of ARDS (Acute Respiratory Distress syndrome). A recent study has shown that patients, sometimes young, requiring hospitalization in intensive care have deregulation of cytokines with very high levels of IL-6, IL-2, IL-7, IL-10 and TNF-α. The cytokines involved in the pathogenesis and clinical manifestations of CRS are mainly IL-6, gamma interferon (IFN-g), tumor necrosis factor alpha (TNF-a) and IL-10.

Although immunoinflammatory therapy is not systematically recommended in pneumonia linked to SARS-CoV-2, given the CRS and the pathophysiological results of pulmonary edema and the formation of the hyaline membrane, a targeted therapeutic approach and temporally accompanied by adequate ventilatory support could be beneficial in patients with severe pneumonia who develop ARDS. Tocilizumab (Roactemra®) is a drug that blocks the IL-6 receptor commonly prescribed for the treatment of rheumatoid arthritis. The intravenous formulation has been approved for the treatment of CRS which occurs during treatment with Car-T; given the clinical picture and cytokine levels in patients with severe SARS-Cov-2 pneumonia, Tocilizumab or another anti-IL6R antagonist may reasonably be expected to contribute to the control of virus-induced Systemic Inflammatory Response Syndrome (SIRS) in patients with elevated levels of IL-6.

The objectivation of high interleukin 6 levels in these patients should be an important scientific argument to justify the administration of therapy based on antagonization of IL6. Measurement of other pro inflammatory cytokines will shed light on the mechanism of the inflammatory syndrome induced by the SARS-CoV-2 virus.

One of the pathophysiological mechanisms of pulmonary pathology could be the induction of the production of complement factors by interleukin 6 as well as the activation of the complement cascade by the virus via the lectin pathway. It is known that one of the effects of Tocilizumab is to reduce the concentration of the various complement factors, the synthesis of which is under the control of interleukin 6. This is why this study proposes to measure certain parameters of the complement (CH50, C3, C4, C3d, C5a, SC5b-9, C4a, MASP-2) in order to objectify and quantify this activation.

If the activation of the complement proves significant it could be an argument for a treatment targeting more specifically the cascade of the complement.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 63
• Est. completion date: November 23, 2020
• Est. primary completion date: November 23, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• End of the initial phase of high viral load of SARS-Cov-2 (for example apyretic> 72h and / or at least 7 days after the onset of symptoms)

• Worsening of respiratory exchanges which require non-invasive or invasive ventilation support (BCRSS score =3)

• High levels of IL-6 (> 40 pg / ml); alternatively high levels of d-dimer and / or PCR and / or ferritin and / or fibrinogen gradually increase.

• A control group will be formed by patients in the Covid unit who do not have respiratory problems justifying a transfer to intensive care.

Exclusion Criteria:

• Documented sepsis caused by other pathogens other than SARS-Corv-2.

• Presence of comorbidities likely to lead, according to clinical judgment, to an unfavorable result

• Immunosuppressive anti-rejection therapy

Related Conditions & MeSH terms

• COVID-19
• Systemic Inflammatory Response Syndrome

Intervention

Diagnostic Test:
• Cytokines dosage
Dosage of inflammatory cytokines and other markers of systemic inflammatory syndromes (TNFa, IFNg, IL1, IL7, IL10, IL12, IL17, sCD25, sCD163, sCD14, IL-6, IL6-R, complex IL6-IL6R, glycolsylated ferritin...).
• Complement dosage
Dosage of the complement parameters: CH50, C3, C4, C3d, C5a, SC5b-9, C4a, MASP-2.

Locations

Country	Name	City	State
Belgium	CHU Brugmann	Brussels

Sponsors (1)

Lead Sponsor	Collaborator
Francis Corazza

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	IL6 concentration	Interleukine 6, soluble IL6-R, complex IL6-IL6R concentration	Before anti-IL6R treatment (baseline)
Primary	IL6 concentration change from baseline value	Interleukine 6 soluble IL6-R, complex IL6-IL6R variation compared to baseline value	Twice a week from day 1 to day 14 post anti-IL6R administration
Primary	Complement parameters	CH50, C3, C4, C3d, C5a, SC5b-9, C4a, MASP-2	Before anti-IL6R treatment (baseline)
Primary	Complement parameters change from baseline values	CH50, C3, C4, C3d, C5a, SC5b-9, C4a, MASP-2 variation compared to baseline values	Twice a week from day 1 to day 14 post anti-IL6R administration
Primary	Inflammatory cytokines baseline concentrations	Concentration of TNFa, IFNg, IL1, IL7, IL10, IL12, IL17, IL18	Before anti-IL6R treatment (baseline)
Primary	Inflammatory cytokines change from baseline values	Concentration of TNFa, IFNg, IL1, IL7, IL10, IL12, IL17, IL18 variation compared to baseline values	Twice a week from day 1 to day 14 post anti-IL6R administration
Secondary	Concentration of markers of macrophage activation	sCD25, sCD163, sCD14, glycosylated ferritin	Before anti-IL6R treatment (baseline)
Secondary	Markers of macrophage activation change from baseline values	sCD25, sCD163, sCD14, glycosylated ferritin variation compared to baseline values	Twice a week from day 1 to day 14 post anti-IL6R administration